#MSCOVID19-Swedish Experience

#

Prof B spoke at the iWiMS for 8 min. Here it is:

And here is a summary of the Swedish data presented by Jan Hillert.

And the following are our crude statistical analyses of the Swedish data:

Despite no correction of confounders the difference between Rituximab and other DMTs in terms of getting COVID-19 is highly significant and therefore likely to be biologically significant (bad news for anti-CD20 therapies).

However, in Swedish patients with COVID-19 the severity of COVID-19, i.e. requiring hospitalisation or ITU, does not appear to be more common in patients treated with rituximab so far. Please be aware that these analyses are based on very low numbers and hence may change in time when more cases are reported.

About the author

MouseDoctor

7 comments

  • Thank you for posting this presentation. Very informative. It is comforting to see the sharing of data among various MS centers and experts.

    MD, I love the new cartoon buggy. Just wish they could travel the Atlantic and pick up test samples for your team to analyze. It is unfortunate that it takes a COVID type event to get MS centers to share and collaborate.

    Thankfully pwms have this blog!

  • It’s getting to the stage where this blog terrifies me and I feel like being on ocrelizumab is now a curse. Waiting for data to see if ITU data etc changes with anti-CD20 …
    Even though we say data is small and results are preliminary, as we now have results from Sweden France Italy UK USA etc, although small numbers in each is it not enough to now say there is reassurance regarding the lack of severe covid in pwMS?
    Are the at risk people not now clearly older and co-morbid?
    At this stage fit people on antiCD20 probably need some positive news too.

    • Fit people on anti-CD20 the positive news if if you do get infected you will probably recover.

      On this blog you have now seen the results of hundeds of people on ocrevus and the general direction is recovery….The real risk has been those who are older and more disabled. This group will have more co-morbidities. In the Swedish group I think the CD20-positive cases were younder rather than older….were they out and about more than other people.

      I think we are seeing data on ocrelizumab because it is popular, I suspect ofatumumab is waiting in the wings, chomping at the bit (a horse eats its bit in the mouth when it is eager to run the race) as it has some useful differences.

      • In your view, is there an important difference outside the way it is administered? Maybe I am missing something, but spending a day in the clinic is vastly preferable to me than going there monthly, even if the subcutaneous injection is much faster… And I do not even live far from the clinic!

        • I suspect the dose may be an issue, one may be too low but in terms of vaccine readiness, not sure about ocrelizumab one will be potentially impaired for a long time, time will tell…for a few second subcutaneous injection would you have to go to the monthly clinic? Surely we can be more inventive

          • I guess that would depend mainly on the co-medication and monitoring requirements.

            With something like ocrelizumab I’d really prefer to do it somewhere where they are familiar with it.

            If it is more like vaccine shot obviously we got more options.

By MouseDoctor

Translate

Categories

Recent Posts

Recent Comments

Archives